BioSyent Schedules Q3 and YTD 2026 Earnings Release for November 17, 2026

Résumé détaillé

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and nine months ended ...

MISSISSAUGA, Ontario, Nov. 10, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and nine months ended September 30, 2026 on Tuesday, November 17, 2026 after market hours. A presentation on the Company’s third quarter and year-to-date 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,235,488 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Début de l'article, extrait de Toronto Star. Pour lire la suite, ouvrez l'article chez le média.